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OBJECTIVE: To evaluate the cost consequences of
LMWH compared with unfractionated heparin in the
treatment of unstable angina pectoris in Japan.
METHODS: A cost-consequence analysis was performed
using decision-analytic modeling using evidence from the
FRISC (Fragmin during Instability in Coronary Artery
Disease) study group, Sweden. The decision tree models a
patient presenting with unstable angina pectoris and fac-
ing the alternative treatments of LMWH or heparin as a
basic model. Also, an advanced model was constructed
with treatment options that reflected more realistic prac-
tice patterns in Japan. Cardiologists reviewed the model-
development process to make the model relevant to the
Japanese medical environment. The direct costs were ob-
tained from pilot studies of DRGs in Japanese national
hospitals.
RESULTS: In the basic model, we estimated a slight dif-
ference in expected costs between LMWH and heparin,
favoring LMWH. However, this model was limited in
two main areas: 1) difference in effects between LMHW
and heparin were not statistically significant in the FRISC
study; 2) opportunity costs such as monitoring for hep-
arinization and treatment of bleeding with heparin were
not included. When we incorporated realistic assump-
tions regarding the opportunity costs and Japan’s treat-
ment patterns, we found that the total medical costs for
the LMWH group were much lower than for the heparin
group even if the clinical effects for heparin and LMWH
were set as equal. In this case, the estimated cost in the
LMWH group was about $11,300 per patient and
$19,600 for the heparin group assuming LMWH is prop-
erly used in clinical practice. This result was robust to a
range of sensitivity analyses.
CONCLUSION: The use of LMWH for unstable angina
pectoris in actual clinical practice where heparin monitoring
can be avoided appears to be cost-saving in Japan. Consid-
ering the target population of 700,000 patients in Japan, the
LMWH will have a great economic impact on society.
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OBJECTIVE: To quantify and qualify the antihyperten-
sive pharmaceutical expenditure incurred for the treat-
ment of a population in the real world.
METHODS: An administrative database, collecting in-
formation on all purchased drugs, was used to perform a
retrospective analysis for each health-assisted subject by
the Ravenna Local Health Unit. By crosschecking with
the registry office and hospital database, gender, age and
previous hospitalizations for cardiovascular diseases were
also made available. All new users over 20 years old re-
ceiving a first prescription for diuretic, beta-blocker, cal-
cium-channel-blocker, angiotensin-converting-enzyme in-
hibitor or angiotensin II antagonist between 01/01/1997
and 12/31/1997 were included. According to persistency
of treatment, patients were classified as continuers (dura-
tion of therapy over 273 days with the initial antihyper-
tensive class), switchers (duration of therapy over 273
days with a different class of antihypertensive than origi-
nally prescribed) and discontinuers (duration of therapy
less than 273 days). The follow-up period lasted 365
days.
RESULTS: A total of 16,783 patients were enrolled, in-
cluding 7409 men (44.1%) and 9374 women (55.9%)
with an average age of 56.1  18.3 years. Continuers
and switchers represented 26.9% and 8.2% of enrolled
subjects, respectively. The percentage of treatment inter-
ruptions (64.9%) ranged from 42.0% with angiotensin II
antagonists to 69.8% with diuretics, and 53.8% of the
population interrupted therapy after the first prescrip-
tion. Age, co-morbidities and previous hospitalizations were
higher for continuers and switchers than for discontinu-
ers. The overall expenditure accounted for €1,076,053.55
of which 54.8% was for continuers, 19.8% for switchers
and 25.4% for discontinuers. The percentage of the over-
all cost for discontinuers ranged from 14.8% with angio-
tensin II antagonists to 30.6% with calcium-channel
blockers.
CONCLUSION: The high percentage of discontinuers
translated into an expense incurred improperly. The high
percentage of interruptions after the first prescription
seemed to indicate that medication prescribed at enroll-
ment was not appropriate.
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Patients’ persistence with chronic treatment is a major
component in the effectiveness assessment.
OBJECTIVE: To evaluate whether the initial choice of
antihypertensive agent impacts newly diagnosed hyper-
tensive patients’ persistence with treatment at one year.
METHODS: The comparisons were between patients ini-
tially prescribed irbesartan, angiotensin II receptor antag-
onists (AIIRA) versus other antihypertensive drugs. We
compared the proportion of patients who remained on
the monotherapy initially prescribed, added to their ini-
tial therapy, switched to another therapy, or discontinued
therapy at one year using chi-squared tests. Monotherapy
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duration was analyzed using Kaplan Meier estimates.
Statistical comparison of the survival curves was done
with the Log-rank test. We pooled IMS Mediplus data
(patient medical records completed by general practitio-
ners) from Germany, France and the United Kingdom for
analysis. Data was obtained for all irbesartan patients
with at least one year of follow-up and from randomly
selected samples of patients treated with either diuretics,
beta blockers, calcium channel blockers, ACE inhibitors,
or other AIIRA. Patients were newly diagnosed with hy-
pertension between October 1, 1997 and November 30,
1998 and initiated antihypertensive treatment as mono-
therapy.
RESULTS: Patients included (2,416) were initiated on di-
uretics (422), beta blockers (441), calcium channel block-
ers (466), ACE inhibitors (333), losartan (188), irbe-
sartan (380), other AIIRA (186). When irbesartan was
prescribed, more patients remained on that therapy
(60.8%) than with all other antihypertensives (44.2%, p 
0.001), or other AIIRAs (51.3%, p  0.009). Compared
to patients taking all other antihypertensives, fewer pa-
tients receiving irbesartan required adjunctive therapy
(16.1% vs 25.3%, p  0.001) or switched therapy (9.0%
vs 13.6%, p  0.013).
CONCLUSIONS: Irbesartan was superior compared to
all antihypertensives in achieving persistence of initial
therapy. By evaluating persistence rather than compli-
ance, we captured both the patient’s and the physician’s
role in determining the course of treatment.
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OBJECTIVE: Controlled clinical trials have demon-
strated the positive impact of statin therapy on health
outcomes in hyperlipidemic patients. The positive impact
of adherence is seemingly intuitive and many programs
have been designed to improve adherence. However,
there are few studies analyzing the cost-effectiveness of
medication-adherence interventions. This decision analy-
sis model will examine the cost-effectiveness of programs
designed to enhance medication adherence in patients
taking statins. The model varies the medication-adher-
ence rate and program costs to determine the differences
in the expected outcome of three different types of inter-
vention.
METHODS: Data from published clinical and pharma-
coeconomic studies were entered into a decision analysis
model. A Monte Carlo simulation using 10,000 trials
was used with beta distributions for the assumptive vari-
ables. The baseline adherence rate was set at 67% and
the cardiovascular event rate at 1.5%. Behavioral (B)
type interventions were assumed to increase adherence by
8.61%, Educational (E) interventions by 11.22% and
Combined (C) B and E by 17.04%. Program costs were
estimated as follows: B  $200, E  $100, and C 
$225 per patient. Cardiovascular and serious medication-
related events were also used as outcomes. The cost-per-
patient-per-event avoided was calculated. ANOVA was
used to test for differences among intervention types.
RESULTS: The results showed that the interventions in-
creased the number of events avoided in the first year by
0.04 (95% CI  0.04,0.12) for B, by 0.06 (95%CI 
0.02, 0.14) for E and by 0.08 (95%CI  0.02, 0.14)
for C. The cost-per-event-per-patient avoided in the first
year of treatment was B  $6,038, E  $2,568 and C 
$3,839. There was a statistical difference among all inter-
vention types with respect to cost of events avoided.
CONCLUSIONS: There was no difference in the number
of events avoided in the first year of statin treatment with
respect to intervention type. While C interventions yielded
more events avoided, E interventions appear to be the
most cost-effective. More study on the cost-effectiveness
of medication adherence programs is required.
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Patients with heart failure suffer from poor health out-
comes due to multiple co-morbidity requiring multiple
medications. Patients who misunderstand their diagnosis
and treatment plan may use their medication subopti-
mally. Providing knowledge through education is one
mechanism that can help patients improve medication
compliance.
OBJECTIVES: To develop and establish measurement
properties of two distinct instruments that can be used in
patients with heart failure (HF) to measure acceptability
of educational materials and subsequent knowledge
gained following an educational intervention.
METHODS: Using an expert panel, we developed mini-
mal criteria required to educate patients with HF. Subse-
quently, we developed and tested two questionnaires.
The first measure, which we refer to as a measure of edu-
cational material acceptability (EMA) was developed to
help us differentiate between booklets designed to edu-
cate patients with HF so as to select which booklets were
most acceptable to the patient. The second measure,
which we refer to as the measure of knowledge acquisi-
tion (MKA), was developed to help us evaluate the im-
pact of our educational intervention on knowledge. MKA
